Project Grant R01HL180397
Award Date 7/15/26
Completion Date 3/31/28
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of California, Los Angeles a $1.56 million Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective July 15, 2026, with completion targeted for March 31, 2028. This award funds basic science research to elucidate the role of noncoding RNA—specifically long noncoding RNAs (lncRNAs) and micropeptides—in cardiovascular disease pathogenesis, with emphasis on lipid metabolism,...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Southern California a $790,498 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, and extending through June 30, 2030. The grant supports basic research investigating the novel role of PCBP1 (poly(C) binding protein 1), an RNA-binding protein, and its splicing target AARS2 in regulating vascular endothelial growth factor (VEGF)...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $1,072,936 to the University of California, San Diego, effective September 15, 2025, through June 30, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports fundamental research investigating protein aggregation mechanisms in hematopoietic stem cells (HSCs), with the primary deliverable being scientific research and discovery designed to advance...
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $736,089 Project Grant to the University of California, Los Angeles on August 15, 2025, to support research on NNMT (Nicotinamide N-Methyltransferase) Inhibition for Treating Heart Failure through the Cardiovascular Diseases Research program (CFDA 93.837). The project, which extends through May 31, 2029, investigates the novel mechanism by which NNMT induction contributes to NAD+ (nicotinamide adenine...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $650,028 Project Grant to the University of California, Los Angeles (UCLA) on September 9, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). This project, titled "Sex-Dependent Regulation of Cardiac cAMP, ECC, and Arrhythmia by Phosphodiesterases," will be conducted through May 31, 2029, at UCLA's Davis, California location. The research will investigate the...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $711,796 Project Grant to the University of California, Irvine, effective July 1, 2026, through April 30, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). The project will develop a nanomaterial-engineered proteomic (NANOPRO) platform designed to map curvature-dependent cardiac signaling by creating unbiased, 20-nanometer-resolution proteomic atlases of distinct membrane...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $1,567,702 to the University of California, Los Angeles, under the Cardiovascular Diseases Research program (CFDA 93.837) on July 15, 2026, with an ultimate completion date of June 30, 2028. This project grant funds research to define the mechanisms underlying cardioneural ablation (CNA)-associated ventricular arrhythmogenesis and to enable safer clinical application of CNA—an emerging...
- Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of California, Los Angeles a $741,473 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective June 15, 2026, with completion targeted for March 31, 2030. The research investigates the mechanisms underlying diastolic dysfunction in heart failure with preserved ejection fraction (HFpEF), focusing on the interplay between nitric oxide synthases (NOS), cyclic nucleotide messengers...
- Federal Project Grant Award Summary Stanford University received $165,488 in funding from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) beginning March 5, 2026, with completion expected by December 31, 2028. This Project Grant supports hypothesis-driven research investigating the role of the transcription factor TCF21 in adventitial fibroblasts and atherosclerosis development. The research deliverables include characterization of...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham a Project Grant of $535,556 under the Cardiovascular Diseases Research program (CFDA 93.837) effective August 1, 2025, with completion targeted for May 31, 2030. This award supports research to elucidate the role of a novel mechanosensitive histone modification (H3T32 O-GlcNAc) in atherosclerosis pathogenesis. The research investigates how atheroprone shear stress...